FindTrial
Sign In

Lasmiditan 100 mg

DRUG2 trials

Sponsors

Eli Lilly and Company

Conditions

Acute MigraineMigraine With or Without Aura

Phase 3

Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
CompletedNCT02439320
Eli Lilly and CompanyAcute Migraine
Start: 2015-04-30End: 2016-08-31Updated: 2019-12-16
Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine
CompletedNCT02605174
Eli Lilly and CompanyMigraine With or Without Aura
Start: 2016-05-31End: 2017-06-30Updated: 2019-09-23

Related Papers

Rimegepant, Ubrogepant, and Lasmiditan in the Acute Treatment of Migraine Examining the Benefit-Risk Profile Using Number Needed to Treat/Harm
Clinical Journal of Pain2022-09-2010 citations
The Association Between the Occurrence of Common Treatment-Emergent Adverse Events and Efficacy Outcomes After Lasmiditan Treatment of a Single Migraine Attack: Secondary Analyses from Four Pooled Randomized Clinical Trials
CNS Drugs2022-07-013 citations
Migraine history and response to lasmiditan across racial and ethnic groups.
2022-04-031 citations
Lasmiditan efficacy in the acute treatment of migraine was independent of prior response to triptans: Findings from the CENTURION study
Cephalalgia2021-10-1320 citations
A close association of freedom from pain, migraine-related functional disability, and other outcomes: results of a post hoc analysis of randomized lasmiditan studies SAMURAI and SPARTAN
The Journal of Headache and Pain2021-08-283 citations
Tolerability and Safety of Lasmiditan Treatment in Elderly Patients With Migraine: Post Hoc Analyses From Randomized Studies.
2021-06-0113 citations
Lasmiditan efficacy in migraine attacks with mild vs. moderate or severe pain.
2021-04-075 citations
Effect of a change in lasmiditan dose on efficacy and safety in patients with migraine
Postgraduate Medicine2021-03-175 citations
Lasmiditan in patients with common migraine comorbidities: a <i>post hoc</i> efficacy and safety analysis of two phase 3 randomized clinical trials.
2020-10-066 citations
Improvement in Function after Lasmiditan Treatment: Post Hoc Analysis of Data from Phase 3 Studies.
2020-05-237 citations
Trajectory of migraine-related disability following long-term treatment with lasmiditan: results of the GLADIATOR study.
2020-02-2426 citations
Lasmiditan for the acute treatment of migraine: Subgroup analyses by prior response to triptans
Cephalalgia2019-11-1952 citations
Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials.
2019-08-2962 citations
Interim results of a prospective, randomized, open-label, Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study)
Cephalalgia2019-08-2195 citations
Effect of a rescue or recurrence dose of lasmiditan on efficacy and safety in the acute treatment of migraine: findings from the phase 3 trials (SAMURAI and SPARTAN)
BMC Neurology2019-08-1328 citations
Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trials
The Journal of Headache and Pain2019-07-2441 citations
Sustained responses to lasmiditan: Results from post-hoc analyses of two Phase 3 randomized clinical trials for acute treatment of migraine
Cephalalgia2019-07-0326 citations
Safety findings from Phase 3 lasmiditan studies for acute treatment of migraine: Results from SAMURAI and SPARTAN
Cephalalgia2019-06-0571 citations
Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine
Brain2019-05-02264 citations
Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study.
2018-11-16171 citations